威斯康星结石生活质量量表与偏好性健康效用测量在肾结石患者中的关系
SF-6D和EQ-5D效用值与WISQOL标准分显著相关(r=0.87和0.58,均P<.0001),WISQOL分别解释SF-6D和EQ-5D效用值变异的72.1%和33.9%。患者及有症状患者的效用值显著低于对照及无症状患者。
要点
- SF-6D效用值与WISQOL标准分强相关(r=0.87),优于EQ-5D(r=0.58)。
- WISQOL标准分可解释SF-6D效用值变异的72.1%。
- 结石患者及有症状患者的SF-6D和EQ-5D效用值均显著低于对照及无症状者。
核心结论
- 在泌尿系结石患者中,SF-6D效用值与疾病特异性WISQOL标准分的关联强于EQ-5D,提示SF-6D更适合用于该人群的偏好性HRQoL评估。
- 效用值在结石疾病中显示出结构效度。
研究设计与样本
- 所有参与者完成SF-36 v2(用于计算SF-6D效用值)和EQ-5D问卷,结石患者额外完成WISQOL。
- 采用Pearson检验和多元线性回归分析评估健康效用值与WISQOL评分的关系。
主要发现
- 结石患者WISQOL标准分均值(SD)为63(29.1),SF-6D效用值为0.68(0.16),EQ-5D效用值为0.83(0.17)。
- SF-6D和EQ-5D效用值与WISQOL标准分显著相关(Pearson r分别为0.87和0.58;均P<.0001)。
- 多元线性回归中,WISQOL标准分是SF-6D和EQ-5D效用值的显著预测因子,分别解释72.1%和33.9%的变异。
- 患者与对照相比,以及有症状与无症状患者相比,SF-6D和EQ-5D效用值中位数均显著更低(均P≤.0009和均P≤.0002)。
临床怎么用
- 在结石患者的偏好性HRQoL评估中,可优先考虑SF-6D而非EQ-5D。
- WISQOL标准分可用于预测效用值,辅助临床决策和成本效用分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine preference-based (utility) assessments of health-related quality of life (HRQoL) in kidney stone patients, and evaluate the association between these and disease specific, psychometric health status-based HRQoL scores (obtained via the Wisconsin Stone Quality of Life [WISQOL]). METHODS: One hundred four adults with urolithiasis, as well as 78 young healthy adults without history of urolithiasis (controls) were consecutively enrolled, meeting the predetermined recruitment goal. Each participant completed the SF-36 v2 (from which SF-6D utility is calculated) and EQ-5D questionnaires, while urolithiasis patients additionally completed the WISQOL. Relationship between health utility and WISQOL scores was evaluated using Pearson's test and multivariable linear regression analysis (MVA). Construct validity of the utilities for urolithiasis was assessed by comparing utilities for patients vs controls, and for symptomatic vs asymptomatic patients. RESULTS: Mean (SD) WISQOL standard score, SF-6D, and EQ-5D utilities in stone patients respectively were 63 (29.1), 0.68 (0.16), and 0.83 (0.17). SF-6D and EQ-5D utilities significantly correlated with WISQOL standard score (Pearson's r = 0.87 and 0.58, respectively; each P <.0001). On MVA, WISQOL standard score was a significant predictor of SF-6D and EQ-5D utilities, explaining 72.1% and 33.9% of the respective variances in the utilities. Median SF-6D and EQ-5D utility were significantly lower in patients vs controls (each P ≤.0009), and in symptomatic vs asymptomatic patients (each P ≤ .0002). CONCLUSION: SF-6D, more so than EQ-5D utilities in urolithiasis patients are strongly associated with disease-specific WISQOL scores, suggesting they are optimal for preference-based HRQoL assessment in this population. Construct validity of the utilities in stone disease was demonstrated.
引用
- Polotti C, Tan B, Borglum N, et al. Relationship Between the Wisconsin Stone Quality of Life (WISQOL) and Preference-Based/Health Utility Measures of Health-Related Quality of Life (HRQoL) in Kidney Stone Patients. Urology. 2020. PMID: 32305539. doi:10.1016/j.urology.2020.03.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。